Research Interests
- Hypertrophic cardiomyopathy
- Mitral valve disease
- Structural heart diseases
- Infective endocarditis
Selected Grants
Percutaneous or Surgical Mitral Valve Repair in Patients with Primary Mitral Regurgitation whose mitral valve has been determined to be suitable for correction by MV repair surgery
Clinical TrialPrincipal Investigator · Awarded by Evalve, Inc · 2021 - 2033Discover- HCM
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2022 - 2030Machine Learning Guided Precision Genetic Testing for Identification of Monogenic Cardiovascular Disorders
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2028Mavacamten & Symptomatic nHCM
Clinical TrialPrincipal Investigator · Awarded by MyoKardia, Inc. · 2023 - 2027MAPLE-HCM(CY6032)
Clinical TrialPrincipal Investigator · Awarded by Cytokinetics, Inc. · 2023 - 2026Redwood - HCM OLE
Clinical TrialPrincipal Investigator · Awarded by Cytokinetics, Inc. · 2021 - 2026MAVA-EXTENSION (MYK-461-007)
Clinical TrialPrincipal Investigator · Awarded by MyoKardia, Inc. · 2019 - 2025HCM Learning Lab
ResearchPrincipal Investigator · Awarded by Cytokinetics, Inc. · 2024 - 2025VALOR-HCM
Clinical TrialPrincipal Investigator · Awarded by MyoKardia, Inc. · 2020 - 2024Symptomatic oHCM and MYK-224
Clinical TrialPrincipal Investigator · Awarded by MyoKardia, Inc. · 2023 - 2024An Open-label Extension Study of Mavacamten Previously Enrolled in Study MYK-461-004 (PIONEER)
Clinical TrialPrincipal Investigator · Awarded by MyoKardia, Inc. · 2018 - 2024This is a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow
Clinical TrialPrincipal Investigator · Awarded by Cytokinetics, Inc. · 2020 - 2024SEQUOIA A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CK-3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
Clinical TrialPrincipal Investigator · Awarded by Cytokinetics, Inc. · 2022 - 2024EXPLORER-HCM (MYK-461-005)
Clinical TrialPrincipal Investigator · Awarded by MyoKardia, Inc. · 2018 - 2023COAPT Continued Access Study (CAS)
Clinical TrialPrincipal Investigator · Awarded by Abbott Vascular Devices · 2018 - 2023HCMR.2 Hypertrophic Cardiomyopathy Registry
ResearchSignificant Contributor · Awarded by MedStar Health Research Institute · 2019 - 2021MyoKardia HCM App
ResearchPrincipal Investigator · Awarded by MyoKardia, Inc. · 2016 - 2021MAVERICK-HCM (MYK-461-006)
Clinical TrialPrincipal Investigator · Awarded by MyoKardia, Inc. · 2018 - 2020Qualitative interviews with patients who have Hypertrophic Cardiomyopathy (HCM)
ResearchPrincipal Investigator · Awarded by MyoKardia, Inc. · 2019 - 2020HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy
Clinical TrialSignificant Contributor · Awarded by ICON Clinical Research, Inc. · 2015 - 2019PIONEER-HCM
Clinical TrialPrincipal Investigator · Awarded by MyoKardia, Inc. · 2016 - 2018A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2014 - 2017HCM Video Development project
ResearchPrincipal Investigator · Awarded by MyoKardia, Inc. · 2016 - 2017MYK-461-001 Hypertrophic Cardiomyopathy and Healthy Volunteers
Clinical TrialPrincipal Investigator · Awarded by MyoKardia, Inc. · 2014 - 2017External Relationships
- American College of Physicians
- American Heart Association
- Bristol-Myers Squibb
- Cytokinetics, Inc.
- ICON CLINICAL RESEARCH PLC
- UpToDate, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.